الفهرس 
Epidemiology and risk factors of lung cancer
Diagnosis of lung cancerOnly 14 pages are availabe for public view
 |  | from | 153 |  |  |
| | | from | 153 | | |
Abstract
This randomized clinical trial aimed to evaluate the effect of palliative concomitant chemoradiotherapy on survival in patients with non-small cell lung cancer. More interestingly was that the current study also evaluated the side effects, toxicity on the general status and quality of life of this patient population.
One hundred and ten patients with lung cancer, planned to receive CCRT in Radiation Oncology and Nuclear Medicine Unit- Ain Shams University Hospitals were categorized into two groups. The first group (study group) in which 55 patients received Arm (A) patients will receive induction chemotherapy with two cycles of carboplatin(AUC6) and paclitaxel 175mg/m²) cycles every 21 day, the third cycle administrated with radiotherapy on day 1, 8 low dose of carboplatin(AUC 2) and paclitaxel 60 mg/m² only two times administrated concomitant with the radiotherapy 42 Gy over 15 fraction over 3 weeks.Arm (B) patients will receive standard-dose fractionation of radiation 60Gy/6 weeks 2Gy once per day with concurrent weekly low dose of carboplatin (AUC 2) and paclitaxel 60 mg/m² followed by two cycles of full doses of carboplatin (AUC 6) /paclitaxel 175mg/ m² every 21 days.
The current study measured parameters included; overall survival, median survival; toxicity and impact of therapy on patient quality of life as measured by a disease specific questionnaire for lung cancer patients.We enrolled 11o patients with stage III NSCLC from 2015 to 2017.the median follow up duration was 24 months is surviving patients.median survival, 2-year OS were in concurrent palliative chemoradiation arm 4.7 and 12.3-months respectively and were 7.3 and 17.6 in concurrent definitive chemoradiatiobn arm respectively (p < 0.01).
HRQOL was better in the palliative arm during the treatment but remained unchanged in both arms I the follow up visits. There were more hospital admissions related to side effects in the definitive arm (p<0.05).